scholarly journals Plasma amyloid‐beta42/40 ratio as biomarker of cerebral amyloidosis in cognitively unimpaired APOE‐e4 homozygotes, heterozygotes and non‐carriers

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Willemijn J. Jansen ◽  
Valentina Ghisays ◽  
Kathryn L. DeMarco ◽  
Connie A. Boker ◽  
Kewei Chen ◽  
...  
Keyword(s):  
Cerebral Amyloidosis

scholarly journals The Role of High Triglycerides Level in Predicting Cognitive Impairment: A Review of Current Evidence

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2118
Author(s):  
Alina Mihaela Dimache ◽  
Delia Lidia Șalaru ◽  
Radu Sascău ◽  
Cristian Stătescu
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Lifestyle Modification ◽  
Cognitive Disorders ◽  
Current Evidence ◽  
Barrier Dysfunction ◽  
Serum Triglycerides ◽  
Cerebral Amyloidosis ◽  
The Relationship

The burden of cognitive disorders is huge and still growing, however the etiology and the degree of cognitive impairment vary considerably. Neurodegenerative and vascular mechanisms were most frequently assessed in patients with dementia. Recent studies have shown the possible involvement of triglycerides levels in cognitive function through putative mechanisms such as brain blood barrier dysfunction or amyloid metabolism imbalance, but not all research in the field found this association. Several clinical studies evaluated the relationship between different forms of cognitive decline and levels of serum triglycerides, independent of other cardiovascular risk factors. This review focuses on the role of triglycerides in cognitive decline, cerebral amyloidosis and vascular impairment. Considering that the management of hypertriglyceridemia benefits from lifestyle modification, diet, and specific drug therapy, future studies are requested to appraise the triglycerides–cognitive impairment relationship.

scholarly journals MyD88 Is Dispensable for Cerebral Amyloidosis and Neuroinflammation in APP/PS1 Transgenic Mice

2014 ◽  
Vol 184 (11) ◽  
pp. 2855-2861 ◽  
Author(s):  
Tara M. Weitz ◽  
David Gate ◽  
Kavon Rezai-Zadeh ◽  
Terrence Town
Keyword(s):  
Transgenic Mice ◽  
Cerebral Amyloidosis

IC-P-026: HIGH BLOOD PRESSURE, BUT NOT CEREBRAL AMYLOIDOSIS, IS ASSOCIATED WITH LATE-LIFE ONSET DEPRESSION IN NON-DEMENTED ELDERLY

2014 ◽  
Vol 10 ◽  
pp. P18-P18
Author(s):  
Min Soo Byun ◽  
Young Min Choe ◽  
Bo Kyung Sohn ◽  
Ji Young Han ◽  
Eun Hyun Seo ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Blood Pressure ◽  
Late Life ◽  
Cerebral Amyloidosis

scholarly journals Prion-like aspects of cerebral amyloidosis

2013 ◽  
Vol 8 (Suppl 1) ◽  
pp. O21
Author(s):  
Mathias Jucker ◽  
Lan Ye ◽  
Sarah Fritschi
Keyword(s):  
Cerebral Amyloidosis

scholarly journals Midlife Plasma Aβ and Late-Life Risk of Cognitive Impairment: The Atherosclerosis Risk in Communities Study

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 251-252
Author(s):  
Kevin Sullivan ◽  
Chad Blackshear ◽  
A Richey Sharrett ◽  
Rebecca Gottesman ◽  
David Knopman ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Standard Deviation ◽  
Sex Education ◽  
Lower Risk ◽  
Late Life ◽  
Cognitive Status ◽  
Cognitive Outcomes ◽  
Effective Population ◽  
Standard Deviation Increase ◽  
Cerebral Amyloidosis

Abstract Plasma-based biomarkers of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer’s disease, show promise in predicting cognitive impairment and mapping onto cerebral amyloidosis, but little is known about how midlife plasma Aβ associates with late-life cognitive outcomes. Midlife plasma variants Aβ42 and Aβ40 were measured using a fluorimetric bead-based immunoassay in a subsample of visit 3 ARIC participants (1993-95; n=2585, mean age=59.4±5.2, 57% female, 23% African American). We investigated the relationship between midlife plasma Aβ and late-life mild cognitive impairment (MCI; n=923) and dementia (n=628) diagnosed from 2011-19. Multinomial logistic regressions estimated relative risk ratios (RRR) of MCI, dementia, and death vs normal cognitive status as a function of:(1) Aβ42:Aβ40 ratio, (2) Aβ42 and Aβ40 included as separate terms, and (3) Protected Aβ group (participants with Aβ42≥46 pg/ml and Aβ40 <233 pg/ml). Adjusters included age, sex, education, site-race, and APOE4. Every doubling of midlife plasma Aβ42:Aβ40 up to a threshold of 0.20 was associated with 41% lower risk of developing MCI/dementia in comparison to cognitively normal (RRR=0.59 [95% CI:0.42, 0.82]), with no association for ratio values ≥0.20. Every standard deviation increase in plasma Aβ42 was associated with 17% lower risk of dementia (RRR=0.83 [0.70, 0.99]), whereas every standard deviation increase in plasma Aβ40 was associated with 16% higher risk of MCI (RRR=1.16 [1.02, 1.31]). The protected midlife plasma Aβ group had 86% lower risk of late-life dementia vs all others (RRR=0.14 [0.04, 0.47]). Early measurement of plasma Aβ may prove an accessible and effective population screener for future cognitive impairment.

scholarly journals The Meta-Memory Ratio: A new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease

2020 ◽  
Author(s):  
Geoffroy Pierre Gagliardi ◽  
Marion Houot ◽  
Federica Cacciamani ◽  
Marie-Odile Habert ◽  
Bruno Dubois ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Clinical Care ◽  
Subjective Memory ◽  
Cerebral Amyloidosis ◽  
Cognitive Awareness ◽  
Amyloid Load ◽  
Asymptomatic Individuals ◽  
The Impact

Abstract Background Lack of Awareness for Cognitive Decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR), and explored how it is associated with neuroimaging AD biomarkers in asymptomatic individuals at risk for AD. Method 448 cognitively healthy participants from two cohorts of subjective memory complainers (INSIGHT-PreAD and ADNI) were included. Regression models were used to assess the impact of AD biomarkers on the MMR. Result In both cohorts, there was a significant quadratic effect of cerebral amyloidosis on the MMR value. In particular, participants had a high ACD up to the amyloid positivity threshold, above which a decrease of ACD was eventually observed as the amyloid load increased. Conclusion This nonlinear evolution of ACD in very early AD must be taken into account in clinical care and for trial enrollment as well.

Preclinical Alzheimer's disease

2014 ◽  
Vol 24 (2) ◽  
pp. 117-121
Author(s):  
P Gil-Gregorio ◽  
R Yubero-Pancorbo
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Diagnostic Criteria ◽  
Stage I ◽  
Disease Stage ◽  
Synaptic Dysfunction ◽  
Preclinical Alzheimer’S Disease ◽  
Cerebral Amyloidosis ◽  
Three Stages

SummaryRecently, diagnostic criteria for preclinical Alzheimer's disease have been proposed. These describe and define three stages of disease. Stage I is focused on asymptomatic cerebral amyloidosis. Stage II includes evidence of synaptic dysfunction and/or early degeneration. Finally, stage III of the disease is characterized by the beginning of cognitive decline.

scholarly journals O3-01-01: INTERACTION BETWEEN OBESITY, BRAIN HDL, AND APOE4 GENOTYPE IN CEREBRAL AMYLOIDOSIS

2019 ◽  
Vol 15 ◽  
pp. P875-P875
Author(s):  
Ashley E. Martinez ◽  
Xulei He ◽  
Trusha Parekh ◽  
Sarah M. King ◽  
Melanie D. Sweeney ◽  
...  
Keyword(s):  
Cerebral Amyloidosis
Sign in / Sign up

Export Citation Format

Share Document